Ro
Direct-to-consumer telehealth platform delivering treatments for weight loss, men's health, dermatology, and fertility.
Healthcare
📍 New York, NY
Founded 2017
Current Valuation
$7.0B
as of 2025
UNICORN
Ro is a direct-to-consumer telehealth platform that diagnoses patients, prescribes treatments, and delivers medication, with a particularly strong franchise in men's health (Roman), weight loss (compounded GLP-1s and Plenity), and fertility (Modern Fertility). Sacra estimates 2024 revenue at $598M (+66% YoY), and the company has held a $7B valuation since its 2022 Series D — well off its 2021 peak — with renewed IPO chatter as GLP-1 demand explodes.
Company Profile
Last Round
Series D — $150M (Feb 2022) · Lead: General Catalyst
Founders & Key People
Zachariah ReitanoSaman RahmanianRob Schutz
Investors
General Catalyst · FirstMark Capital · ShawSpring Partners · Tiger Global · TQ Ventures · BoxGroup
Products
- Roman (men's health & ED)
- Ro Body (GLP-1 weight loss)
- Plenity
- Modern Fertility
- Ro Pharmacy
- Workpath at-home diagnostics
Competitors
Hims & Hers · Noom · Teladoc · Lemonaid Health · Form Health
telehealthGLP-1weight-lossDTCpharmacy
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025. Refreshed quarterly.